Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview in-person at the 34th Annual Roth Conference, which is being held at The Ritz Carlton, Laguna Niguel located in Dana Point, California on March 13-15, 2022.
聖迭戈，2022年3月8日(環球通訊社)--專注於開發基於免疫的預防和治療疾病療法的臨牀期生命科學公司啟示錄生物科學公司(納斯達克代碼：REVIB)(以下簡稱“公司”或“啟示錄”)今天宣佈，其首席執行官詹姆斯·羅克將在第34屆羅思年會上親自介紹公司概況，該會議正在達納的尼日利亞拉古納湖麗思卡爾頓酒店舉行。
34th Annual Roth Conference Presentation Details
第34屆羅斯年會演講細節
| Date: | Tuesday, March 15, 2022 | |
| Time: | 8:00 a.m. Pacific Time | |
| Location: | Blue – Salon 2 @ The Ritz Carlton, Laguna Niguel | |
| Webcast: | REVB Webcast Link |
| 日期： | 2022年3月15日(星期二) | |
| 時間： | 上午8點太平洋時間 | |
| 位置： | 藍色沙龍2@拉古納尼格爾麗思卡爾頓酒店 | |
| 網絡直播： | Revb網絡廣播鏈接 |
A live webcast of the presentation will also be available in the Investor Relations section of Revelation's website at A replay of the presentation will be available on Revelation's website for 30 days following the event.
演示文稿的現場網絡直播還將在Infoation公司網站的投資者關係欄目中進行，在活動結束後的30天內，演示文稿的重播將在Infoation公司的網站上進行。
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.
羅爾克先生將在整個會議期間面對面和虛擬地參加一對一會議。
About Revelation Biosciences Inc.
關於啟示錄生物科學公司
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation's therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
啟迪生物科學公司是一家臨牀階段的生命科學公司，專注於開發基於免疫學的預防和治療疾病的療法。啟示錄有幾款候選產品正在開發中。REVTx-99是主要的候選治療藥物，是一種鼻腔免疫調節劑，用於預防或治療由各種呼吸道病毒引起的感染，如SARS-CoV-2，包括其變種、甲型和乙型流感、副流感、鼻病毒和呼吸道合胞病毒。REVTx-99還被開發用於其他適應症，如：過敏性鼻炎和慢性鼻塞。REVTx-200是一種鼻腔免疫調節劑輔助劑，可與肌肉注射疫苗結合使用，以獲得更完全的免疫力。REVTx-200基於與REVTx-99相同的技術。除了啟示號的治療流水線外，啟示號還在開發REVDx-501，這是一種快速的家庭使用診斷方法，可以用來檢測任何呼吸道病毒感染，無論病毒類型或毒株，而不需要專門的儀器。
For more information on Revelation, please visit .
有關啟示錄的更多信息，請訪問。
Company Contacts
公司聯繫人
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
桑德拉·韋德里克(Sandra Vedrick)
投資者關係和人力資源部副總裁
啟示錄生物科學公司。
電子郵件：svedrick@revbiosciences.com
and
和
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
切斯特·齊格蒙特(Chester Zygmont)，III
首席財務官
啟示錄生物科學公司。
電子郵件：czygmont@revbiosciences.com
